prostatic cancer
Conditions
Interventions
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1)Age =18 years old; 2) Diagnosed with prostate cancer; 3) The investigator assessed the availability of rivirumide therapy, or was receiving or is receiving rivirumide therapy; 4) Sign informed consent and voluntarily join the study; 5) Male patients whose partner is a fertile woman should be surgically sterilized or consent to be given during and at the end of the trial
Exclusion criteria
Exclusion criteria: Patients were excluded from this study if they had any of the following: 1) Participating in other revirumide related clinical studies; 2) Other situations that the researcher determines are not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| PSA index: PSA response rate, time to PSA progression;Survival and image-related endpoints: Duration of medication (DOT) until initiation of the first follow-up anti-prostate cancer therapy Interval, rPFS (Investigator assessment), MFS, OS, objective response rate of soft tissue lesions; | — |
Countries
China
Contacts
Public ContactXu Zhang
Chinese PLA General Hospital
Outcome results
None listed